# DEA Schedule I Synthetic Cannabinoids Control Update June 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update-june-2026/ > **Published:** 2026-06-19T13:04:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:31-04:00 > **Clinical Summary:** Review the DEA Schedule I synthetic cannabinoids control update from June 19, 2026, highlighting key regulatory changes and clinical implications. --- Policy WatchJune 19, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis. [Read more →](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2026/01/20/2026-00954/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur for cannabinoids or related compounds. [Read more →](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino) Score 70Federal Register [Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in illicit cannabis products, into Schedule I, impacting its legality and clinical use. [Read more →](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/10/15/2025-19542/schedules-of-controlled-substances-temporary-placement-of-ethyleneoxynitazene-methylenedioxynitazene) Score 70Federal Register [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and legal considerations regarding cannabinoid products. [Read more →](https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/08/15/2025-15566/schedules-of-controlled-substances-temporary-placement-of-n-pyrrolidino-metonitazene-and) Score 70Federal Register [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and) Score 70Federal Register [Exempt Chemical Preparations Under the Controlled Substances Act](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/07/01/2025-12198/exempt-chemical-preparations-under-the-controlled-substances-act) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i) (No summary available.) [Read more →](https://www.federalregister.gov/documents/2025/06/26/2025-11462/schedules-of-controlled-substances-temporary-placement-of-seven-benzimidazole-opioids-in-schedule-i) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011) (No summary available.) [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011) Digest-Level Clinical Commentary Dr. Caplan’s Take These regulatory actions predominantly address synthetic cannabinoids, novel benzodiazepines, and emerging opioid analogs rather than cannabis itself, reflecting the DEA’s focus on designer drugs that often pose greater acute toxicity and addiction liability than traditional cannabis. As a [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioner, I interpret this pattern as regulatory clarity that distinguishes cannabis from the increasingly dangerous synthetic compounds circulating in unregulated markets, which helps inform evidence-based conversations with patients about relative risk profiles. The proliferation of these scheduling actions underscores why cannabis’s Schedule I status appears increasingly incongruous with its clinical applications and safety profile relative to these newly scheduled substances, though this observation does not diminish the legitimate [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) concerns driving these enforcement priorities. Clinical Perspective Clinical Perspective on [Controlled Substance Scheduling](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) Trends The regulatory actions documented here reflect an ongoing effort to address the proliferation of synthetic drugs designed to circumvent existing controlled substance laws through minor chemical modifications. These substances, primarily synthetic cannabinoids, benzodiazepines, cathinones, opioids, and nitazenes, represent a persistent [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) challenge characterized by rapid innovation in clandestine chemistry that outpaces formal scheduling procedures. From a clinical standpoint, the pattern of temporary placements followed by permanent scheduling underscores the lag between emergence of novel psychoactive substances and their regulatory control, during which clinicians encounter increasing numbers of patients with toxidromes from unfamiliar compounds that lack established safety or efficacy data. Drug EnforcementSynthetic Drugs[Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/)Regulatory Affairs 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+June+19%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+June+19%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 20 Regulatory Updates — June 21, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/) Stay informed with the latest regulatory updates following June 19, 2026, including new developments in [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/). [Read the June 21 Update](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/) [Policy Watch: 20 Regulatory Updates — June 06, 2026](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-june-2026/) Review earlier June regulatory actions that set the stage for the latest DEA scheduling decisions affecting synthetic cannabinoids. [Explore June 06 Updates](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-june-2026/) [DEA Places Four Synthetic Cannabinoids in Schedule I](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update/) Detailed analysis of the DEA’s placement of synthetic cannabinoids into Schedule I, highlighting clinical and regulatory impacts. [Learn More About DEA Scheduling](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).